| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Pasithea Therapeutics (NASDAQ:KTTA) through any online brokerage.
Other companies in Pasithea Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Pasithea Therapeutics has a consensus price target of $3.00.
The stock price for Pasithea Therapeutics (NASDAQ: KTTA) is $0.44 last updated October 22, 2026 at 7:42 PM EDT.
There are no upcoming dividends for Pasithea Therapeutics.
Pasithea Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Pasithea Therapeutics.
Pasithea Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
